在复发性复发性多发性硬化症中,ocrelizumab与natalizumab对比:与注册表相关联的电子健康记录研究
medRxiv : the preprint server for health sciences
|December 18, 2025
概括
与natalizumab相比,ocrelizumab在两年内复发性复发性多发性硬化症 (RRMS) 患者的残疾进展风险较低. 这项现实世界的研究强调了ocrelizumab.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 数据科学数据科学数据科学
背景情况:
- 复发性复发性多发性硬化症 (RRMS) 用高效的疾病修饰疗法 (DMT) 治疗,如ocrelizumab和natalizumab.
- 这些DMT在减少残疾进展方面的直接比较有效性数据有限.
- 电子健康记录 (EHR) 往往缺乏关键的亚型和残疾数据,阻碍了真实世界的证据 (RWE) 生成.
研究的目的:
- 为了比较ocrelizumab与natalizumab在缓解RRMS患者残疾进展方面的两年有效性.
- 为了利用纵向注册表链接的EHR数据进行可靠的比较分析.
- 通过使用先进的归算技术,解决电子健康记录中的数据缺口.
主要方法:
- 使用大型医疗保健系统数据的回顾性队列研究.
- 开发了一种集体机器学习模型,以归因缺失的RRMS亚型和残疾结果 (EDSS).
- 采用半监督的双重稳健方法来估计平均治疗效果,调整混因素.
主要成果:
- 与纳塔利祖马布治疗的患者 (n=205) 相比,接受奥克雷祖马布治疗的患者 (n=543) 的两年中度/重度残疾风险显著降低 (风险差异: -5.87%).
- 在使用归算和观察到的扩展残疾状况量表 (EDSS) 结果的灵敏度分析中,研究结果一致.
- 探索性分析表明,Rituximab的类似趋势.
结论:
- 在现实环境中,ocrelizumab在RRMS患者中与natalizumab相比,显示残疾进展的风险较低.
- 该研究验证了一个新的归算框架,用于生成RWE,尽管缺少数据.
- 这种方法为未来在复杂的临床群体中进行RWE研究提供了一条途径.
相关概念视频
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Methods of Documentation VII: EMR
1.4K
Electronic Medical Records (EMRs) primarily center around electronically documenting patients' health information within a single healthcare organization or practice. They contain essential clinical data related to a patient's medical history, diagnoses, medications, treatment plans, lab results, and other pertinent information relevant to the specific encounter or episode of care. EMRs are designed to streamline documentation and workflow processes within individual healthcare...
1.4K
Bioequivalence of Drugs: Drugs with Multiple Indications
141
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
141
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
445
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
445


